[ad_1]
MELBOURNE, Australia & SAN FRANCISCO – (BUSINESS WIRE) – July 8, 2018 – Prana Biotechnology Ltd. (ASX PBT: NASDAQ PRAN) announced today that it will present further preclinical evidence for the PBT434 at the International Congress of Parkinson's Disease and Movement Disorders® to be held in Hong Kong from 5 to 9 October 2018.
Data to be presented will include new in vivo evidence of the effectiveness of PBT434 to prevent the loss of neurons and to improve an animal model of multisystem atrophy (MSA), a major cause of atypical parkinsonism. MSA is a rapidly progressive and devastating neurological disease without any established treatment and is one of the target indications for PBT434
PBT434 is the first of a new generation of small molecules designed to inhibit aggregation alpha (α) -synuclein and tau, vital intracellular proteins that are implicated in neurodegenerative diseases such as Parkinson's disease and atypical parkinsonism. PBT434 has been shown to reduce the abnormal accumulation of these proteins in animal models of the disease by restoring the normal balance of iron in the brain. Previous non-clinical characterization of PBT434, including animal models of Parkinson's disease, was published last year in Acta Neuropathologica Communications and can be found at https://doi.org/10.1186/s40478-017 -0456-2.
The experimental data to be presented demonstrate that in an animal model of MSA, PBT434 prevents the accumulation of α-synuclein, preserves neurons and decreases the number of inclusions of glial cells in the brain of treated animals. Glial cell inclusions are the main pathological finding in MSA and contain an abundant aggregated α-synuclein badociated with neurodegeneration. Importantly, these benefits have led to an improvement in motor function in treated animals. Alpha-synuclein is of great interest because aggregated forms of the protein are considered a pathological hallmark of Parkinson's pathologies and are a therapeutic target recognized by both basic and clinical neuroscientists.
"Multisystemic atrophy is a devastating orphan disease. limited treatment options. These animal data are robust and indicate that PBT434 has excellent potential for helping people with AMS. Having recently begun our first human study on PBT434, these data represent an important step in the pursuit of new treatments for Parkinson's disease, "said David Stamler, Chief Medical Officer and Vice President of Clinical Development.
initial human study of PBT434 began in June 2018.
The International Congress on Parkinson's Disease and Movement Disorders is the main scientific meeting to share ideas and stimulate interest in care and research on Disorders of the Movement
For further information, please visit the Society's website: www.pranabio.com
CONTACT: for Prana Biotechnology Ltd
Ben Walsh, +61 422 520 012 [19659003] Scott Newstead, +61 3 9866 4722
KEY TEXT: AUSTRALIA UNITED STATES ASIA PACIFIC NORTH AMERICA AUSTRALIA / OCEANIA CALIFORNIA HONG KONG
KEY WORDS BY INDUSTR IE: HEALTH BIOTECHNOLOGY HOSPITALS MED DEVICES HERE MEDICAL PHARMACEUTICAL SUPPLIES
SOURCE: Prana Biotechnology Ltd.
Copyright Business Wire 2018.
PUB: 07/08/2018 8:15 PM / DISC: 07/08/2018 8:15 PM
Copyright Business Wire 2018.
[ad_2]
Source link
